Article Text
PDF
Statistics from Altmetric.com
Q Do selective cyclo-oxygenase-2 (COX 2) inhibitors increase risk of serious vascular events more than placebo or traditional non-steroidal anti-inflammatory drugs (NSAIDs)?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★★ Haematology ★★★★★☆☆ Rheumatology ★★★★★★★
METHODS
Data sources:
Medline and EMBASE/Excerpta Medica (1966 to April 2005), US Food and Drug Administration website, and drug manufacturers.
Study selection and assessment:
randomised controlled trials (RCTs) ⩾4 weeks in duration that compared a selective COX 2 inhibitor with placebo or a traditional NSAID. 138 RCTs (n = 145 373) met the selection criteria. Investigators and manufacturers provided details on the number of vascular events and person time at risk.
Outcomes:
myocardial infarction (MI), stroke, and vascular death, and a composite end point of all vascular events.
MAIN RESULTS
Selective COX 2 inhibitors increased risk …
Footnotes
-
For correspondence: Dr C Baigent, University of Oxford, Oxford, UK. colin.baigent{at}ctsu.ox.ac.uk
-
Sources of funding: UK Medical Research Council; British Heart Foundation; Cancer Research UK.